XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborations with Third Parties (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 02, 2024
Apr. 26, 2021
Apr. 17, 2020
Jan. 02, 2019
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2020
Collaborations with Third Parties              
Total Revenues         $ 116,334 $ 75,475  
Subsequent Event              
Collaborations with Third Parties              
First milestone payment $ 100,000            
Time required to pay cash portion 15 days            
Second milestone payment $ 25,000            
Royalty Revenue From DSE And Sale Of Bulk Tablets              
Collaborations with Third Parties              
Total Revenues         37,200 18,200  
Collaboration Revenue              
Collaborations with Third Parties              
Total Revenues         37,999 19,612  
Minimum | Subsequent Event              
Collaborations with Third Parties              
Aggregate payment agreement 125,000            
Daiichi Sankyo Europe GmbH ("DSE") | Subsequent Event              
Collaborations with Third Parties              
Potential one-time cash payment upon milestone $ 300,000            
Daiichi Sankyo Europe GmbH ("DSE") | Minimum | Subsequent Event | Commitment Offering              
Collaborations with Third Parties              
Royalties on sales 15.00%            
Daiichi Sankyo Europe GmbH ("DSE") | Maximum | Subsequent Event | Commitment Offering              
Collaborations with Third Parties              
Royalties on sales 25.00%            
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement              
Collaborations with Third Parties              
Upfront cash payment       $ 150,000      
Cash payment to the Company             $ 150,000
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement | Minimum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales       15.00%      
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement | Maximum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales       25.00%      
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities              
Collaborations with Third Parties              
Upfront cash payment     $ 60,000        
Potential additional future payments     $ 450,000        
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Collaboration Revenue              
Collaborations with Third Parties              
Total Revenues         100 600  
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Minimum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales     15.00%        
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Maximum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales     30.00%        
Milestone payment, first JNDA submissions     $ 20,000        
Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory     70,000        
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label     50,000        
Milestone payments related to total net sales achievements     $ 310,000        
Daiichi Sankyo Co. Ltd | Collaborative Arrangement              
Collaborations with Third Parties              
Total Revenues         $ 700 $ 800  
Consideration cash payment   $ 30,000          
Payment to be received upon milestone   $ 175,000          
Daiichi Sankyo Co. Ltd | Collaborative Arrangement | Minimum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales   5.00%          
Daiichi Sankyo Co. Ltd | Collaborative Arrangement | Maximum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales   20.00%